With the proliferation of data available today and strides in technology leading to advances in healthcare, we are discussing how government agencies can leverage real-world data (RWD) and Privacy-Preserving Record Linkage (PPRL) technology to preserve and promote public health. In the second installment of this five-part series, we are going to delve deeper into disease surveillance for a rapid response to outbreaks.
As mentioned in our introduction to this series, government public health agencies can monitor RWD to understand disease spread, predict potential outbreaks and allocate resources when threats to public health arise from outbreaks, such as COVID-19, Mpox (formerly known as Monkeypox) or respiratory syncytial virus (RSV). In times of disaster, such as the COVID pandemic, government agencies can face unnecessary challenges if starting from scratch when accumulating the data they need to monitor and manage the situation. In addition to current data sources curated by government agencies (state registries, electronic case reporting, etc.), the government needs to leverage traditionally fragmented RWD sources, such as medical and pharmacy claims, electronic medical records (EMRs), labs and more.
The government has made significant investments in innovative surveillance programs, such as the National Syndromic Surveillance Program (NSSP), collecting data from over 6,400 healthcare facilities, the National Wastewater Surveillance System, monitoring for COVID outbreaks in major cities, and the Vaccine Adverse Event Reporting System (VAERS), a self-reporting system aimed at monitoring vaccine safety. As agencies continue to advance disease surveillance, there are many data requirements to consider.
There are a number of considerations when leveraging RWD for disease surveillance. For optimal disease surveillance, government agencies need:
While individual data sources have yielded some positive results, given the fragmentation of healthcare data, one data source alone cannot address all of the above concerns. Government agencies need to consider a variety of data sources, and be able to synchronize it while managing privacy considerations.
Each data source has unique attributes that also need to be considered when selecting data for disease surveillance:
For optimal disease surveillance that allows for rapid response times and detailed insight on a maximum number of patients, aspects of each data type above are needed, but historically, agencies could only procure a single, siloed data source or had to analyze individual datasets separately, without the ability to quickly and reliably sync patients across data sources.2 PPRL technology empowers government agencies to realize the true potential of RWD by synchronizing data from multiple sources while meeting privacy regulations. This allows the positive features in each data type to come to life to create a comprehensive, fast-reacting dataset needed for disease surveillance.
As mentioned in the introduction to this series, not all PPRL technologies are alike and there are certain gold standards. Because HealthVerity de-identifies patient records using a universal patient identifier, known as a HealthVerity ID (HVID), and matches the HVID to a continuously updated referential database consisting of over 200 billion healthcare and consumer transactions, our PPRL technology is 10x more accurate than legacy tokenization techniques and our data ecosystem, representing more than 75 unique data sources, is fully interoperable and HIPAA compliant. This synchronized approach also allows agencies to weave in their own data or data from other third-party sources, such as regional health systems. Our cutting-edge PPRL technology has been implemented by several government agencies, including the CDC for disease surveillance during the COVID-19 pandemic. Click here to learn more about this and other PPRL projects.
In the next installment of our five-part series, we will discuss how RWD and PPRL technology can help government agencies monitor drug safety.
Click here to learn more about how HealthVerity can support disease surveillance or your agency's other data initiatives.
1Fang, H., Frean, M., Sylwestrzak, MA. (2022). Trends in Disenrollment and Reenrollment Within US Commercial Health Insurance Plans, 2006-2018. JAMA Network Open. February 24, 2022. 2022;5(2):e220320. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789399
2Maximus (2023). Executive survey: Agencies want data that can lead to actionable intelligence. https://maximus.com/sites/default/files/documents/Federal/data-for-actionable-intelligence-fnn-executive-survey-final.pdf